CalciMedica, Inc. 8-K

What Happened
CalciMedica, Inc. announced in an 8‑K that Nasdaq notified the company it is not in compliance with listing standards because its market value of listed securities fell below the $35,000,000 minimum and its common stock traded below the $1.00 minimum bid price. The market value notice was received March 13, 2026 (180‑day cure period to September 9, 2026), and the minimum bid price notice was received March 16, 2026 (180‑day cure period to September 14, 2026). The company’s shares continue trading on Nasdaq under the symbol “CALC.”

Key Details

• Nasdaq Listing Rule 5550(b)(2) violation: MVLS below the $35,000,000 minimum for 30 consecutive business days; 180‑day cure window ends Sept 9, 2026.
• Alternative ways to regain MVLS compliance: maintain stockholders’ equity ≥ $2,500,000 (Rule 5550(b)(1)) or report net income from continuing operations ≥ $500,000 in the most recent year or two of three years (Rule 5550(b)(3)).
• Nasdaq Listing Rule 5550(a)(2) violation: minimum bid price below $1.00 for 30 consecutive business days; 180‑day cure window ends Sept 14, 2026. Regain by closing ≥ $1.00 per share for 10 consecutive business days.
• If the initial bid‑price cure fails, a second 180‑day period may be available if other initial listing criteria (except bid price) are met and the company notifies Nasdaq of intent to cure. Company may consider actions such as a reverse stock split.

Why It Matters
Notices of non‑compliance signal a risk that CalciMedica’s Nasdaq listing could be jeopardized if the company does not meet the cure conditions within the specified periods. For investors, failure to regain compliance could lead to delisting, reduced liquidity, and potential downward pressure on the stock. The filings are procedural notifications — trading continues — but they highlight near‑term milestones (Sept 9 and Sept 14, 2026) to watch and potential corporate actions (e.g., reverse split) management might take to restore compliance.